Editors' ChoiceCancer

Targeting the Tumor Microenvironment

See allHide authors and affiliations

Science Translational Medicine  11 Nov 2009:
Vol. 1, Issue 6, pp. 6ec21
DOI: 10.1126/scitranslmed.3000560

You are currently viewing the summary.

View Full Text

Summary

A Stat3-stifling siRNA augmented with an oligonucleotide agonist of a Toll-like receptor stimulates tumor-destroying immune responses.